Table 2.
Clinicopathologic variables and DND1 expression in 83 prostate cancer patients.
| Variable | Group | DND1 expression | P value# | ||
|---|---|---|---|---|---|
| n | Low | High | |||
| Age | <70 | 55 | 23 (27.7%) | 32 (38.6%) | 0.065 |
| ≥70 | 28 | 6 (7.2%) | 22 (26.5%) | ||
|
| |||||
| Perioperative PSA | ≤10 | 20 | 9 (10.8%) | 11 (13.3%) | 0.279 |
| >10 | 63 | 20 (24.1%) | 43 (51.8%) | ||
|
| |||||
| Clinical stage | T2 | 22 | 13 (15.7%) | 9 (10.8%) | 0.006∗ |
| T3-4 | 61 | 16 (19.3%) | 45 (54.2%) | ||
|
| |||||
| ISUP grading group | ISUP1-2 | 41 | 27 (32.5%) | 14 (16.9%) | <0.001∗ |
| ISUP3-5 | 42 | 2 (2.4%) | 40 (48.2%) | ||
|
| |||||
| Seminal vesicle invasion | Absence | 12 | 0 (0%) | 12 (14.5%) | 0.006∗ |
| Presence | 71 | 29 (34.9%) | 42 (50.6%) | ||
|
| |||||
| Lymph node metastasis | Absence | 6 | 0 (0%) | 6 (7.2%) | 0.087 |
| Presence | 77 | 29 (34.9%) | 48 (57.8%) | ||
|
| |||||
| Bone metastasis | Absence | 6 | 1 (1.2%) | 5 (6%) | 0.596 |
| Presence | 77 | 28 (33.7%) | 49 (59.0%) | ||
# P value was analyzed by the chi-square test. ∗P < 0.05 with statistical significance.